Diligence memo · auto-generated · as of July 2, 2026
BioMarker Strategies LLC
BioMarker Strategies LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
BioMarker Strategies LLC operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BioMarker Strategies LLC has raised $7.9M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.3M on 2011-08-09.
Most recent recorded round closed around 2016-08-23.
Valuation (modeled)modeled
Provath models BioMarker Strategies LLC at approximately $23M (range $378K–$183M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.33× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 9.9 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 52% of Biotechnology peers (4293 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.